Levodopa: 50 years of a revolutionary drug for Parkinson disease

Movement Disorders

Volumn 30, Issue 1, 2015, Pages 1-3

  Fahn, Stanley ^a   Poewe, Werner ^b  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMINO ACID DECARBOXYLASE; CATECHOL METHYLTRANSFERASE; DOPAMINE; LEVODOPA; NEUROMELANIN; ANTIPARKINSON AGENT;

AWARENESS; BASAL GANGLION; DEGENERATIVE DISEASE; EDITORIAL; HUMAN; INVOLUNTARY MOVEMENT; MEDICAL SCHOOL; MOTOR DYSFUNCTION; NEUROTRANSMISSION; PARKINSON DISEASE; PHYSICIAN; PRIORITY JOURNAL; RACEMIC MIXTURE; SUBSTANTIA NIGRA; VIDEORECORDING; HISTORY;

ANTIPARKINSON AGENTS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LEVODOPA; PARKINSON DISEASE;

EID: 84920925765     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26122     Document Type: Editorial

References (18)

1. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967;276:374-379.
2. Cotzias GC, Papavasiliou PS, Gellene R. Modification of parkinsonism - chronic treatment with L-dopa. N Engl J Med 1969;280:337-345.
3. Yahr MD, Duvoisin RC, Schear MJ, Barrett RE, Hoehn MM. Treatment of parkinsonism with levodopa. Arch Neurol. 1969 Oct;21(4):343-54.
4. Ehringer H, Hornykiewicz O: Verteilung von Noradrenalin und Dopamin (3-Hydroxytryamin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 38:1238-1239, 1960.
5. Birkmayer W, Hornykiewicz O. Der L-3, 4-Dioxyphenylalanin (DOPA)-Effekt bei der Parkinson-Akinese. [The effect of L-3, 4-dihydroxyphenylalanine (= DOPA) on akinesia in parkinsonism.] Wien Klin Wochenschr 1961;73:787-788.
6. McGeer PL, Zeldowicz LR. Administration of dihydroxyphenylalanine to parkinsonian patients. Canad Med Assn J 1964;90:463-466.
7. Fahn S. The medical treatment of Parkinson disease from James Parkinson to George Cotzias. Mov Disord. 2014, this issue.
8. Parkinson J. An Essay on the Shaking Palsy, London, Sherwood, Neely, and Jones, 1817.
9. Lees AJ, Tolosa E, Olanow CW. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias and Melvin Yahr. Mov Disord. 2014, this issue.
10. Olanow CW. Levodopa: Effect on cell death and the natural history of Parkinson disease. Mov Disord. 2014, this issue.
11. Mosharov EV, Borgkvist A, Sulzer D. Presynaptic effects of L-DOPA and their possible role in dyskinesia. Mov Disord. 2014, this issue.
12. Ko JH, Lerner RP, Eidelberg D. Effects of levodopa on regional cerebral metabolism and blood flow. Mov Disord. 2014, this issue.
13. LeWitt PA. Levodopa therapy for Parkinson disease: pharmacokinetics and pharmacodynamics. Mov Disord. 2014, this issue.
14. Stoessl AJ. Central pharmacokinetics of levodopa: lessons from imaging studies. Mov Disord. 2014, this issue.
15. Aquino CC, Fox SH. Clinical spectrum and underlying mechanisms of levodopa-induced complications. Mov Disord. 2014, this issue.
16. Beaulieu-Boire I, Lang AE. Behavioral effects of levodopa. Mov Disord. 2014, this issue.
17. Gershanik OS. Improving L-dopa therapy - the development of enzyme inhibitors. Mov Disord. 2014, this issue.
18. Poewe W, Antonini A. Novel formulations and modes of delivery of levodopa. Mov Disord. 2014, this issue.